Oryzon Genomics S.A. (0RDB.L)
| Chiusura precedente | 2,5331 |
| Aperto | 2,4450 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 2,4450 - 2,5195 |
| Intervallo di 52 settimane | 2,4450 - 2,5195 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 920.564 |
| Beta (5 anni mensile) | 1,06 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0880 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a broad collaboration with The Cancer Epigenetics Institute (CEI) MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the f
- GlobeNewswire
ORYZON to Give Updates on Corporate Progress in January
6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2023 MADRID, Spain and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress
- GlobeNewswire
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
Eurostars-3 collaborative project with Danish institutions ImProTher and University of Copenhagen Global budget of 1.4 million euros; Oryzon to receive up to 400,000 euros Project will assess the efficacy of iadademstat in combination with checkpoint inhibitors and/or oncological vaccines MADRID, Spain and BOSTON, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseas
